Growth hormone
Somatrogon
A GH fusion protein with a pediatric growth trial supporting noninferiority to daily somatropin, within a defined margin.
Randomized pediatric GH-deficiency trial; noninferiority evidence
Also known as: Ngenla · Somatrogon-ghla
Practical use
Clinical context and evidence interpretation
- Look beyond the average
- Read the confidence interval and noninferiority margin beside the reported cm/year.
- Record experience as well as growth
- Bring dated measurements, injection-site complaints and changes in daily function to the pediatric endocrine review.
- Avoid a false product ranking
- Ask whether a comparison comes from one direct trial or from unrelated studies with different participants and follow-up.
Overview
Somatrogon joins the GH sequence to peptide segments that prolong its circulation; it still acts through the GH receptor. US Ngenla labeling covers children aged three and older with growth failure from inadequate GH secretion. The label reviewed here does not create an adult performance indication.
Risks and limitations
Injection-site pain and other GH-related effects matter. Warnings include glucose intolerance, intracranial hypertension, fluid retention, thyroid/adrenal changes and neoplasm concerns. Active malignancy and closed growth plates are contraindications. A child’s new limp or persistent headache with visual symptoms needs prompt assessment.
How to read this
The clinically relevant question is growth in children with diagnosed deficiency, alongside tolerability and treatment burden. A sustained IGF-1 response is not itself proof of better strength, athletic performance or general health.
Research explained
Global phase III growth comparison
Who was studied
228 prepubertal children with GH deficiency randomized; 224 received treatment. Somatrogon was compared with daily somatropin in an open-label 12-month study.
- Somatrogon: height velocity
- 10.1 cm/year
- Daily somatropin: height velocity
- 9.78 cm/year
What was found
Annualized height velocity was 10.10 versus 9.78 cm/year. The adjusted difference was 0.33 cm/year (95% CI −0.24 to 0.89), meeting the −1.8 cm/year noninferiority margin. Most reported adverse events were mild or moderate.
What it cannot establish
The confidence interval includes no difference: this is not proof of superior growth. The open-label study and one-year endpoint do not establish final height or exclude uncommon longer-term harms.
Read the original studyWhat the confidence interval adds
Although the average favored somatrogon, the interval crossed zero. The supported interpretation is noninferiority within the study’s margin rather than a demonstrated growth advantage.
Supporting sourceThe fusion protein is a distinct medicine
Somatrogon is not simply another name for somatropin or for another long-acting GH product. Product-specific evidence and labeling are needed for comparisons.
Supporting sourceClaims versus findings
Not established
A numerically higher growth rate proves somatrogon is better.
The uncertainty interval included no difference, while the study was designed around a noninferiority criterion.
Check the evidenceCommon questions
Does raising IGF-1 mean any adult can gain height?
No. The approved pediatric context requires growth failure from GH deficiency, and closed growth plates are a contraindication.
SourceSources
Global phase III growth comparison
US prescribing information; checked October 1, 2026
Sources checked 2026-10-01.
General education; not a personal treatment plan.